SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy

被引：12

作者：

Hope, Thomas A. ^{[1
]}

Antonarakis, Emmanuel S. ^{[2
]}

Bodei, Lisa ^{[3
]}

Calais, Jeremie ^{[4
]}

Iravani, Amir ^{[5
]}

Jacene, Heather ^{[6
,7
]}

Koo, Phillip J. ^{[8
]}

Morgans, Alicia K. ^{[9
]}

Osborne, Joseph R. ^{[10
]}

Tagawa, Scott T. ^{[11
]}

Taplin, Mary-Ellen ^{[9
]}

Sartor, Oliver ^{[12
]}

Morris, Michael J. ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

[2] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA

[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA

[4] UCLA, David Geffen Sch Med, Dept Mol & Med Pharmacol, Ahmanson Translat Theranost Div, Los Angeles, CA USA

[5] Univ Washington, Dept Radiol, Seattle, WA 98195 USA

[6] Brigham & Womens Hosp, Dept Radiol, Boston, MA USA

[7] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA

[8] Banner MD Anderson Canc Ctr, Phoenix, AZ USA

[9] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[10] Weill Cornell Med, Mol Imaging & Therapeut, Dept Radiol, New York, NY USA

[11] Weill Cornell Med Coll, Dept Med, New York, NY USA

[12] Mayo Clin, Rochester, MN USA

[13] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷 / 09期

关键词：

RESISTANT PROSTATE-CANCER; SURVIVAL; CABAZITAXEL; SAFETY;

D O I：

10.2967/jnumed.123.265952

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Prostate-specific membrane antigen (PSMA) is a transmem-brane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan [Pluvicto; Novartis]) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) after progressing on taxane-based chemotherapy and at least 1 line of androgen recep-tor pathway inhibitors (ARPIs). This document aims to provide standardized guidance through expert consensus for the selection and management of patients being treated with 177Lu-PSMA RLT.

引用

页码：1417 / 1423

页数：7

共 50 条

[41] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
Ngoc, Christina Nguyen
Happel, Christian
Davis, Karen
Groener, Daniel
Mader, Nicolai
Mandel, Philipp
Tselis, Nikolaos
Gruenwald, Frank
Sabet, Amir
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[42] Production and radiochemical purity of 177Lu-PSMA-617 for clinical trial
Asad, Ali
Scharli, Rainer
Morandeau, Laurence
Price, Roger
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S527
[43] The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition
Czernin, Johannes
Calais, Jeremie
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 343 - 343
[44] Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists
Nguyen, Jennifer
Patel, Jeetvan
Kang, Barinder
Yu, Channing
Sawhney, Amrita
Fallick, Mark
Gorritz, Magdaliz
Chen, Chi-Chang
Paltanwale, Queenie
Sun, Kainan
Shore, Neal D.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Value of Post-Therapy Quantitative SPECT for Monitoring Response to 177Lu-PSMA-617 Therapy
Meyer, Catherine
Yilmaz, Burcak
Szidonya, Laszlo
Winters, Celeste
Mench, Anna
Mallak, Nadine
Mittra, Erik
JOURNAL OF NUCLEAR MEDICINE, 2024, 65
[46] Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC A Proof-of-Principle Application
Bal, Chandrasekhar
Yadav, Madhav Prasad
Ballal, Sanjana
CLINICAL NUCLEAR MEDICINE, 2016, 41 (08) : E386 - E387
[47] Patient-specific tumor dosimetry in mCRPC patients treated with 177Lu-PSMA-617
Meyer, Catherine
Mirando, David
Adams, Tim
Czernin, Johannes
Calais, Jeremie
Dahlbom, Magnus
JOURNAL OF NUCLEAR MEDICINE, 2021, 62
[48] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
Qu, Gengcuo
Hua, Qingchu
Li, Hongmei
Zhang, Yu
Chen, Yue
CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
[49] Whole-Body Dosimetry in Therapy of Metastatic Prostate Cancer with 177Lu-PSMA-617
Happel, C.
Voeller, L.
Kranert, W. T.
Groener, D.
Bockisch, B.
Mader, N.
Gruenwald, F.
Sabet, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S695 - S695
[50] Does Pre-Therapy PSA Influence 177Lu-PSMA-617 Treatment Outcomes?
Fermawi, S.
Buehner, T.
Kalarn, S.
Sabottke, C.
Recio-Boiles, A.
Savir-Baruch, B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S363 - S363

← 1 2 3 4 5 →